Natixis Cel Sci Corp Transaction History

Natixis

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 12, 2021	SELL	$7.64 - $12.49 $373,596 - $610,761	-48,900 Closed	0 $0
Q2 2021 Aug 13, 2021	BUY	$8.68 - $27.49 $424,452 - $1.34 Million	48,900 New	48,900 $424,000
Q1 2021 May 14, 2021	SELL	$12.0 - $27.64 $794,400 - $1.83 Million	-66,200 Closed	0 $0
Q4 2020 Feb 12, 2021	BUY	$11.05 - $16.62 $731,510 - $1.1 Million	66,200 New	66,200 $772,000

27.1K

150K

Ticker CVM
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,367,500
Market Cap $26.9M
Description
CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical ...

Get notified when there are updates to the investment portfolio of Natixis, based on Form 13F filings with the SEC.

Stay updated on Natixis with notifications on news.